← Back to Search

Serine Protease Inhibitor

Camostat Mesilate for Coronavirus (RECOVER Trial)

Phase 2
Waitlist Available
Led By Alan H Bryce, M.D.
Research Sponsored by Alan Bryce
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Laboratory confirmed SARS-CoV-2 infection
Admitted to hospital for management of SARS-CoV-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 and 56 days
Awards & highlights

RECOVER Trial Summary

This study is evaluating whether a drug which inhibits a gene may help treat severe acute respiratory syndrome.

RECOVER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

RECOVER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 and 56 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 and 56 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the proportion of patients alive and free from respiratory failure
Secondary outcome measures
Adverse Events
Change in the proportion of patients alive and free of ventilator use or ECMO
Clinical Change
+1 more

Side effects data

From 2021 Phase 2 trial • 70 Patients • NCT04353284
9%
Pruritus
3%
Shortness of Breath
3%
Respiratory Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Camostat Mesylate
Placebo

RECOVER Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Camostat + Standard of CareExperimental Treatment1 Intervention
Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
Group II: Placebo + Standard of CarePlacebo Group1 Intervention
Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Alan BryceLead Sponsor
Alan H Bryce, M.D.Principal InvestigatorAcademic and Community Cancer Research United

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~57 spots leftby Mar 2025